Isomorphic Labs, a London, UK-based AI-first drug design and development company, raised $600M in funding.
The round was led by Thrive Capital, with participation from GV, and existing investor Alphabet.
The company intends to use the funds to accelerate its AI research and development, to advance its AI drug design engine, and expand its team.
Led by CEO and Founder Isomorphic Labs, Isomorphic Labs has built an AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing capabilities to advance drug design.
It has an office in Lausanne, Switzerland.
FinSMEs
31/03/2025